Schering-Plough fertility drug aces Phase III

Schering-Plough's corifollitropin alfa--a fertility drug--met its primary endpoints in a Phase III non-inferiority trial. Corifollitropin alfa is a sustained follicle stimulant and was tested in 1509 patients. The ongoing pregnancy rate, the primary endpoint of the trial, obtained in the 150 mcg corifollitropin alfa treatment arm (38.9 percent per started cycle) was similar to that achieved in patients receiving 200 IU recombinant FSH (follitropin beta) (38.1 percent per started cycle). The results were presented at the European Society of Human Reproduction and Embryology conference.

- see the release for more

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.